Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study
Abstract Background Data are limited on the association of metabolic dysfunction-associated fatty liver disease (MAFLD) with systemic atherosclerosis. This study aimed to examine the relationship between MAFLD and the extent of atherosclerotic plaques and stenosis, and presence of polyvascular disea...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-023-02083-0 |
| _version_ | 1797388563388563456 |
|---|---|
| author | Yanli Zhang Zhang Xia Xueli Cai Xin Su Aoming Jin Lerong Mei Jing Jing Suying Wang Xia Meng Shan Li Mengxing Wang Tiemin Wei Yongjun Wang Yan He Yuesong Pan |
| author_facet | Yanli Zhang Zhang Xia Xueli Cai Xin Su Aoming Jin Lerong Mei Jing Jing Suying Wang Xia Meng Shan Li Mengxing Wang Tiemin Wei Yongjun Wang Yan He Yuesong Pan |
| author_sort | Yanli Zhang |
| collection | DOAJ |
| description | Abstract Background Data are limited on the association of metabolic dysfunction-associated fatty liver disease (MAFLD) with systemic atherosclerosis. This study aimed to examine the relationship between MAFLD and the extent of atherosclerotic plaques and stenosis, and presence of polyvascular disease (PolyVD). Methods In this cross-sectional study, MAFLD was diagnosed based on the presence of metabolic dysfunction (MD) and fatty liver disease (FLD). MAFLD was divided into three subtypes: MAFLD with diabetes mellitus (DM), MAFLD with overweight or obesity (OW), as well as MAFLD with lean/normal weight and at least two metabolic abnormalities. Atherosclerosis was evaluated, with vascular magnetic resonance imaging for intracranial and extracranial arteries, thoracoabdominal computed tomography angiography for coronary, subclavian, aorta, renal, iliofemoral arteries, and ankle-brachial index for peripheral arteries. The extent of plaques and stenosis was defined according to the number of these eight vascular sites affected. PolyVD was defined as the presence of stenosis in at least two vascular sites. Results This study included 3047 participants, with the mean age of 61.2 ± 6.7 years and 46.6% of male (n = 1420). After adjusting for potential confounders, MAFLD was associated with higher extent of plaques (cOR, 2.14, 95% CI 1.85–2.48) and stenosis (cOR, 1.47, 95% CI 1.26–1.71), and higher odds of presence of PolyVD (OR, 1.55, 95% CI 1.24–1.94) as compared with Non-MAFLD. In addition, DM-MAFLD and OW-MAFLD were associated with the extent of atherosclerotic plaques and stenosis, and presence of PolyVD (All P < 0.05). However, lean-MAFLD was only associated with the extent of atherosclerotic plaques (cOR, 1.63, 95% CI 1.14–2.34). As one component of MAFLD, FLD per se was associated with the extent of plaques and stenosis in participants with MAFLD. Furthermore, FLD interacted with MD to increase the odds of presence of systemic atherosclerosis (P for interaction ≤ 0.055). Conclusions MAFLD and its subtypes of DM-MAFLD and OW-MAFLD were associated with the extent of atherosclerotic plaques and stenosis, and presence of PolyVD. This study implicated that FLD might be a potential target of intervention for reducing the deleterious effects of MAFLD on systemic atherosclerosis. |
| first_indexed | 2024-03-08T22:42:37Z |
| format | Article |
| id | doaj.art-bc3746dfb5e849478b1c75a7d0e46483 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-03-08T22:42:37Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-bc3746dfb5e849478b1c75a7d0e464832023-12-17T12:05:52ZengBMCCardiovascular Diabetology1475-28402023-12-0122111110.1186/s12933-023-02083-0Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional studyYanli Zhang0Zhang Xia1Xueli Cai2Xin Su3Aoming Jin4Lerong Mei5Jing Jing6Suying Wang7Xia Meng8Shan Li9Mengxing Wang10Tiemin Wei11Yongjun Wang12Yan He13Yuesong Pan14Department of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityDepartment of Neurology, The Fifth Affiliated Hospital of Wenzhou Medical UniversityDepartment of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityCerebrovascular Research Lab, The Fifth Affiliated Hospital of Wenzhou Medical UniversityDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Neurology, The Fifth Affiliated Hospital of Wenzhou Medical UniversityDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityCerebrovascular Research Lab, The Fifth Affiliated Hospital of Wenzhou Medical UniversityDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Cardiology, The Fifth Affiliated Hospital of Wenzhou Medical UniversityDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityDepartment of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical UniversityAbstract Background Data are limited on the association of metabolic dysfunction-associated fatty liver disease (MAFLD) with systemic atherosclerosis. This study aimed to examine the relationship between MAFLD and the extent of atherosclerotic plaques and stenosis, and presence of polyvascular disease (PolyVD). Methods In this cross-sectional study, MAFLD was diagnosed based on the presence of metabolic dysfunction (MD) and fatty liver disease (FLD). MAFLD was divided into three subtypes: MAFLD with diabetes mellitus (DM), MAFLD with overweight or obesity (OW), as well as MAFLD with lean/normal weight and at least two metabolic abnormalities. Atherosclerosis was evaluated, with vascular magnetic resonance imaging for intracranial and extracranial arteries, thoracoabdominal computed tomography angiography for coronary, subclavian, aorta, renal, iliofemoral arteries, and ankle-brachial index for peripheral arteries. The extent of plaques and stenosis was defined according to the number of these eight vascular sites affected. PolyVD was defined as the presence of stenosis in at least two vascular sites. Results This study included 3047 participants, with the mean age of 61.2 ± 6.7 years and 46.6% of male (n = 1420). After adjusting for potential confounders, MAFLD was associated with higher extent of plaques (cOR, 2.14, 95% CI 1.85–2.48) and stenosis (cOR, 1.47, 95% CI 1.26–1.71), and higher odds of presence of PolyVD (OR, 1.55, 95% CI 1.24–1.94) as compared with Non-MAFLD. In addition, DM-MAFLD and OW-MAFLD were associated with the extent of atherosclerotic plaques and stenosis, and presence of PolyVD (All P < 0.05). However, lean-MAFLD was only associated with the extent of atherosclerotic plaques (cOR, 1.63, 95% CI 1.14–2.34). As one component of MAFLD, FLD per se was associated with the extent of plaques and stenosis in participants with MAFLD. Furthermore, FLD interacted with MD to increase the odds of presence of systemic atherosclerosis (P for interaction ≤ 0.055). Conclusions MAFLD and its subtypes of DM-MAFLD and OW-MAFLD were associated with the extent of atherosclerotic plaques and stenosis, and presence of PolyVD. This study implicated that FLD might be a potential target of intervention for reducing the deleterious effects of MAFLD on systemic atherosclerosis.https://doi.org/10.1186/s12933-023-02083-0Fatty liver diseaseMetabolic dysfunctionAtherosclerosisPolyvascular diseaseDiabetes mellitus |
| spellingShingle | Yanli Zhang Zhang Xia Xueli Cai Xin Su Aoming Jin Lerong Mei Jing Jing Suying Wang Xia Meng Shan Li Mengxing Wang Tiemin Wei Yongjun Wang Yan He Yuesong Pan Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study Cardiovascular Diabetology Fatty liver disease Metabolic dysfunction Atherosclerosis Polyvascular disease Diabetes mellitus |
| title | Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study |
| title_full | Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study |
| title_fullStr | Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study |
| title_full_unstemmed | Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study |
| title_short | Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study |
| title_sort | association of metabolic dysfunction associated fatty liver disease with systemic atherosclerosis a community based cross sectional study |
| topic | Fatty liver disease Metabolic dysfunction Atherosclerosis Polyvascular disease Diabetes mellitus |
| url | https://doi.org/10.1186/s12933-023-02083-0 |
| work_keys_str_mv | AT yanlizhang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT zhangxia associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT xuelicai associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT xinsu associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT aomingjin associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT lerongmei associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT jingjing associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT suyingwang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT xiameng associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT shanli associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT mengxingwang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT tieminwei associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT yongjunwang associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT yanhe associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy AT yuesongpan associationofmetabolicdysfunctionassociatedfattyliverdiseasewithsystemicatherosclerosisacommunitybasedcrosssectionalstudy |